Related Experiment Video
Updated: Jun 19, 2025
08:25
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
Published on: September 9, 2020
11.0K
Liquid Biopsies Based on Cell-Free DNA Integrity as a Biomarker for Cancer Diagnosis: A Meta-Analysis
Ana María Rodríguez-Ces1,2,3, Óscar Rapado-González1,2,3,4,5, Ángel Salgado-Barreira6,7,8
1Department of Surgery and Medical-Surgical Specialties, Medicine and Dentistry School, Universidade de Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain.
Diagnostics (Basel, Switzerland)
|July 27, 2024
Summary
Cell-free DNA integrity (cfDI) in liquid biopsies shows promise for non-invasive cancer diagnosis. This meta-analysis confirms cfDI
Area of Science:
- Oncology
- Molecular Diagnostics
- Biomarker Discovery
Background:
- Liquid biopsies offer a non-invasive method for detecting cancer biomarkers.
- Cell-free DNA integrity (cfDI) is an emerging biomarker in liquid biopsies.
- Accurate diagnostic tools are crucial for early cancer detection and management.
Purpose of the Study:
- To evaluate the diagnostic accuracy of cfDI in liquid biopsies for cancer detection.
- To synthesize existing evidence through a comprehensive meta-analysis.
Main Methods:
- A systematic literature search was performed across major databases (PubMed, Embase, Web of Science, Cochrane Library) up to June 2024.
- Data from 46 studies (72 study units) involving 4286 cancer patients were analyzed.
- Study quality was assessed using QUADAS-2, and meta-regression explored heterogeneity; a bivariate random-effect model was used for diagnostic outcomes.
Main Results:
- The pooled sensitivity for cfDI in cancer diagnosis was 0.70, with a specificity of 0.77.
- Positive and negative likelihood ratios were 3.26 and 0.34, respectively.
- The area under the curve (AUC) was 0.84, indicating good diagnostic performance, with a diagnostic odds ratio of 10.63.
Conclusions:
- The cfDI index demonstrates significant potential as a non-invasive and accurate diagnostic tool for cancer.
- Further validation in diverse clinical settings is warranted to establish cfDI as a routine diagnostic marker.
- Liquid biopsies utilizing cfDI represent a promising advancement in oncological diagnostics.
